Cart
sales@molnova.com
Epimedin A
CAS No. 110623-72-8
Epimedin A( —— )
Catalog No. M17817 CAS No. 110623-72-8
Epimedin A has anti-osteoporosis activities in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 79 | In Stock |
|
| 2MG | 33 | In Stock |
|
| 5MG | 51 | In Stock |
|
| 10MG | 86 | In Stock |
|
| 25MG | 140 | In Stock |
|
| 50MG | 200 | In Stock |
|
| 100MG | 296 | In Stock |
|
| 200MG | 436 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEpimedin A
-
NoteResearch use only, not for human use.
-
Brief DescriptionEpimedin A has anti-osteoporosis activities in vivo.
-
DescriptionEpimedin A has anti-osteoporosis activities in vivo.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPLK
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number110623-72-8
-
Formula Weight838.8
-
Molecular FormulaC39H50O20
-
Purity>98% (HPLC)
-
SolubilityMethanol : 62.5 mg/mL 74.51 mM;
-
SMILESc1(c(c(=O)c2c(o1)c(c(cc2O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)CC=C(C)C)O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO)[C@H](O)[C@@H](O)[C@@H](O1)C)c1ccc(cc1)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Li HB1, Chen F.Separation and purification of epimedin A, B, C, and icariin from the medicinal herb Epimedium brevicornum maxim by dual-mode HSCCC.J Chromatogr Sci. 2009 May-Jun;47(5):337-40.
molnova catalog
related products
-
Tebanicline
Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.
-
Centrinone-B
Centrinone-B (LCR-323) is a potent and highly selective PLK4 inhibitor with a Ki of 0.59 nM.
-
TC-S 7005
TC-S 7005 is an inhibitor of Polo-like kinases (IC50s: 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively).
